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A B S T R A C T
Background
Schizophrenia and related disorders affect a sizable proportion of any population. Antipsychotic medications are the primary treatment
for these disorders. Antipsychotic medications are associated with a variety of adverse effects including tardive dyskinesia. Dyskinesia is a
disfiguring movement disorder of the orofacial region that can be tardive (having a slow or belated onset). Tardive dyskinesia is difficult
to treat, despite experimentation with several treatments. Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil,
flunarizine) have been among these experimental treatments.
Objectives
To determine the effects of calcium channel blocker drugs (diltiazem, nifedipine, nimodipine, verapamil) for treatment of neuroleptic-
induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder or other chronic mental illnesses.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017), inspected references of all identified studies
for further trials and contacted authors of trials for additional information.
Selection criteria
We selected randomised controlled trials comparing calcium channel blockers with placebo, no intervention or any other intervention
for people with both tardive dyskinesia and schizophrenia or serious mental illness who remained on their antipsychotic medication.
Data collection and analysis
We independently extracted data and estimated risk ratios of dichotomous data or mean differences (MD) of continuous data, with
95% confidence intervals (CI). We assumed that people who left the trials early had no improvement. We also created a ’Summary of
findings’ table using GRADE.
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Main results
Previous versions of this review included no trials. From the 2015 search, we identified three cross-over trials that could be included.
The 2017 search found no new studies relevant to this review. The included trials randomised 47 inpatients with chronic mental
illnesses in the USA and China. Trials were published in the 1990s and were of short duration (six to 10 weeks). Overall, the risk of
bias was unclear, mainly due to poor reporting; allocation concealment was not described, generation of the sequence was not explicit,
studies were not clearly blinded, and attrition and outcome data were not fully reported. Findings were sparse, no study reported on the
primary outcome ’no clinically important improvement in tardive dyskinesia symptoms,’ but two small studies (37 participants) found
no difference on the tardive dyskinesia symptoms scale Abnormal Involuntary Movement Scale (AIMS) scores between diltiazem or
flunarizine and placebo after three to four weeks’ treatment (MD -0.71, 95% CI -2.68 to 1.26, very low quality evidence). Only one
study randomising 20 participants reported on adverse events, and reported that there were no adverse events with flunarizine or with
placebo (very low quality evidence). One study with 18 participants reported no events of deterioration in mental state with diltiazem
or with placebo (very low quality evidence). No studies reported on acceptability of treatment or on social confidence, social inclusion,
social networks or personalised quality of life outcomes designated important to patients.
Authors’ conclusions
Available evidence from randomised controlled trials is extremely limited and very low quality, conclusions cannot be drawn. The
effects of calcium channel blockers for antipsychotic-induced tardive dyskinesia are unknown. Their use is experimental and should
only be given in the context of well-designed randomised trials.
P L A I N L A N G U A G E S U M M A R Y
Calcium channel blockers for antipsychotic-induced tardive dyskinesia
Review question
Are a group of medicines called calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil, flunarizine) useful for the
treatment of an unpleasant side effect, tardive dyskinesia, in people with schizophrenia or similar mental health problems?
Background
People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). These symptoms are
usually treated with antipsychotic medicines. However, these drugs can have debilitating side effects. Tardive dyskinesia is an involuntary
movement that causes the face, mouth, tongue and jaw to convulse, spasm and grimace. It is caused by long-term or high-dose of
antipsychotic medicines, is difficult to treat and can be incurable. A group of medicines called calcium channel blockers (diltiazem,
nifedipine, nimodipine, verapamil, flunarizine) have been used as experimental treatments for tardive dyskinesia.
Study characteristics
We searched for clinical trials (up to April 2017) using Cochrane Schizophrenia’s specialised register of trials. The review includes three
small, short trials published in the 1990s. The trials randomised 47 people with schizophrenia or other chronic mental illnesses who
had also developed tardive dyskinesia because they were taking antipsychotic medicines. The treatments the participants received were
the calcium channel blockers, flunarizine, nifedipine or diltiazem hydrochloride or placebo (dummy treatment).
Key results
A small set of very low quality data were available from three small and poorly reported trials. Currently, it is uncertain whether calcium
channel blockers are helpful in the treatment of tardive dyskinesia that is caused by taking antipsychotic medicines. Therefore, the use
of calcium channel blockers for this purpose remains experimental.
Quality of the evidence
Evidence was limited and small scale. It is not possible to recommend these drugs as a treatment for antipsychotic-induced tardive
dyskinesia. To fully investigate whether calcium channel blockers have any positive effects, there would have to be more well-designed,
conducted and reported clinical trials.
This plain language summary was adapted by the review authors from a summary originally written by BenGray, Senior Peer Researcher,
McPin Foundation (mcpin.org/).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Calcium channel blocking drugs for people with antipsychotic- induced tardive dyskinesia
Patient or population: people with ant ipsychot ic-induced tardive dyskinesia
Settings: inpat ients in China (1 study) and the Netherlands (1)
Intervention: calcium channel blocking drugs
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Calcium channel
blocking drugs
Tardive dyskinesia -
not improved to a clini-
cally important extent
No data f rom randomised trials for not improved to a clinically important
extent. 2 RCTs found no signif icant dif f erence on the cont inuous AIMS
scale (MD -0.71, 95% CI -2.68 to 1.26, 2 RCTs, 37 part icipants, I2 = 0%).
37 part icipants
(2 studies)
⊕©©©
Very low 1,2,3
-
Tardive dyskinesia -
deteriorat ion
No data f rom randomised trials.
Adverse effects - any
important adverse ef -
fects
Follow-up: 4 weeks
See comment See comment Not est imable 20 part icipants
(1 study)
⊕©©©
Very low 4,5
1 study reported that
there were no adverse
events.
Adverse effects - im-
portant extrapyramidal
adverse ef fects
No data f rom randomised trials.
Mental state - deterio-
rat ion
Follow-up: 3 weeks
See comment See comment Not est imable 18 part icipants
(1 study)
⊕©©©
Very low 5,6
1 study reported that
no part icipants deterio-
rated in mental state
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Acceptability of treat-
ment - leaving the study
early
No data f rom RCTs.
Social confidence, so-
cial inclusion, social
networks or person-
alised quality of life
measures - no clinically
signif icant change
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AIMS: Abnormal Involuntary Movement Scale; CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias: the included study did not adequately describe randomisat ion or blinding of outcome
assessors, in one study, non-compliant part icipants (3/ 18) were excluded and replaced during the study.
2 Downgraded two levels for imprecision: very small sample size, and wide 95%CIs that may have contained both appreciable
benef it and no ef fect.
3 Downgraded one level for indirectness: results on the cont inuous AIMS scale is not a direct measure of the outcome.
4 Downgraded one level for risk of bias: the included study did not adequately describe allocat ion concealment or blinding of
outcome assessors, and non-compliant part icipants (3/ 18) were excluded and replaced during the study.
5 Downgraded two levels for imprecision: very small sample size, and ef fect could not be est imated due to no reported events.
6 Downgraded one level for risk of bias: the included study did not adequately describe randomisat ion or blinding of outcome
assessors.
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B A C K G R O U N D
Antipsychotic drugs are effective in treating and preventing relapse
of schizophrenia and related psychoses (Schooler 1993). However,
antipsychotic medications are associated with adverse effects that
negatively affect quality of life and may lead to poor compliance;
thus, ultimately, increasing the risk of relapse of people taking
these medications (Barnes 1993). Some of the most troublesome
adverse effects associated with antipsychotic medications involve
movement disorders. The appearance of these disorders can be
extremely disfiguring, can compound stigma and is associatedwith
poor compliance to antipsychotic treatment (Barnes 1993; Tarsy
2011).
Description of the condition
Dyskinesia is a movement disorder characterised by involuntary,
repetitive bodymovements that canbe tardive (having a slow or be-
lated onset). Tardive dyskinesia (TD) is characterised by repetitive,
involuntary, purposeless movements, such as grimacing, tongue
protrusion, lip smacking, puckering and pursing of the lips, and
rapid eye blinking. Rapid movements of the extremities and im-
paired movements of the fingers may also occur. TD tends to be a
chronic condition of insidious onset, the severity of which spon-
taneously fluctuates (APA 1992). Orofacial dyskinesia and trunk
and limb dyskinesia may have different responses to treatment
(APA 1992; Jeste 1982).
TD is often seen as an adverse effect of long-term or high-dose
use of antipsychotic drugs. Within the first four years of using
antipsychotic drugs, 18.5% of young adults and 31% of people
over 55 years of age developTD (Saltz 1991). It has been estimated
that with each year of antipsychotic use, 5% of people will show
signs of TD, (i.e. 5% after one year, 10% after two years and
15% after three years) with no clear upper limit (Jeste 1993).
The incidence of TD varies with the type of antipsychotic drug.
However, among newer atypical antipsychotics, only clozapine has
been shown to have a lower risk of TD than older antipsychotic
drugs (Fernandez 2003; Rauchverger 2007). TD may persist for
months, years or even permanently after withdrawal of the drug,
and it can result in considerable social and physical disability (
Barnes 1993).
Description of the intervention
TD is difficult to treat. Several strategies have been advocated for
treating the disorder, including changing an affected person’s med-
ication (Soares-Weiser 2006), or using many different treatments.
A wide range of experimental treatments has been tried for TD;
most remain unproven and this is one of a series of reviews in this
area (Table 1).
Calcium channel blockers (diltiazem, nifedipine, nimodipine, ve-
rapamil, Figure 1) have important indications in cardiovascular
disorders. Clinical trials of various calcium channel blockers in
people with TD were stimulated by case reports of unexpected
benefit. For instance, one study of four participants suggested that
nifedipine may be effective in the treatment of antipsychotic-in-
ducedTD in people with schizophrenia (Suddath 1991). This sug-
gestion was reinforced by similar low-quality studies (Cates 1993;
Hendrickson 1994). However, when assessing the clinical efficacy
of calcium channel blockers for TD, it should be remembered that
these drugs could cause serious adverse effects, such as a decrease
in blood pressure (hypotension), headaches, nausea, vomiting, de-
pression and even an increase in signs of TD.
5Calcium channel blockers for antipsychotic-induced tardive dyskinesia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Calcium channel blockers.
How the intervention might work
Antipsychotic drugs are claimed to cause an imbalance in certain
chemical receptor sites in the brain, specifically dopamine sites
where there is overactivity, and cholinergic sites, where there is
underactivity (Casey 1994; Cates 1993). Laboratory research sug-
gests that TD may result primarily from antipsychotic-induced
dopamine supersensitivity in the nigrostriatal pathway, with the
D2 dopamine receptor being most affected. Older ’typical’ an-
tipsychotics, which have greater affinity for the D2 binding site,
are associated with high risk for TD (Hoerger 2007).
Animal and human experiments have suggested that intracellu-
lar calcium ions inside the brain cells play a role in the regula-
tion of dopamine and choline activity (Alexander 1979; Dubovsky
1988). Calcium channel blockers show intrinsic dopamine-block-
ing properties (Dubovsky 1988), and their effect on dopamine
neurotransmission has been proposed as a biological basis for
their potential therapeutic effect in TD (Snyder 1985; Tamminga
2002). However, calcium channel blockers are pharmacologically
different. For instance, verapamil crosses the blood-brain barrier
more readily than diltiazem or nifedipine and exhibits dopamine-
antagonist properties (Wolf 1988). These differential effects stim-
ulated clinical studies of the anti-tardive-dyskinesia effect of vera-
pamil (Barrow 1986; Buck 1988). For example, in 13 treatment-
refractorymenwith schizophrenia, TD improved three weeks after
supplementing their chlorpromazine treatment with verapamil,
and rebounded following verapamil discontinuation (Wolf 1988).
One comparison between verapamil and diltiazem demonstrated
a statistically significant reduction in TD ratings with verapamil
but not with diltiazem (Adler 1988).Diltiazemwas also ineffective
in one double-blind, placebo-controlled, cross-over study (Falk
1988), and studies with nifedipine have likewise been disappoint-
ing. Moreover, verapamil itself showed no clinically or statistically
significant changes in antipsychotic-induced TD in seven adults
with mental retardation (Ricketts 1995). In addition, it is feasible
that any improvement related to the use of calcium channel block-
ers for the treatment of TDmay result from drug interactions with
coprescribed antipsychotic medication (Stedman 1991). Such a
feasibility argues against using calcium channel blockers for the
treatment of antipsychotic-induced TD.
Why it is important to do this review
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Schizophrenia and related disorders affect a sizable proportion of
any population. Antipsychotic medications are the primary treat-
ment for these disorders, and TD is a common adverse effect of
this treatment. Despite experimenting with a wide variety of in-
terventions (Table 1), there is still no satisfactory treatment for
TD. Calcium channel blockers have been among the experimental
interventions for TD.
Despite suggested potential benefits, the quality of evidence for
the use of calcium channel blockers in the treatment of TD is yet
to be determined. This review provides practitioners and patients
with the best available evidence for the effects of calcium channel
blockers in antipsychotic-induced TD in people with schizophre-
nia and related disorders.
O B J E C T I V E S
To determine the effects of calcium channel blocker drugs (e.g. dil-
tiazem, nifedipine, nimodipine, verapamil) for treatment of neu-
roleptic-induced tardive dyskinesia in people with schizophrenia,
schizoaffective disorder or other chronic mental illnesses.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCT) that assessed the beneficial
and harmful effects of calcium channel blockers in the treatment
of antipsychotic-induced TD, with no restrictions on blinding,
publication status or language.
Types of participants
People with schizophrenia, schizoaffective disorder or other
chronic mental illnesses, diagnosed by any criteria, irrespective of
gender, age or nationality who developed TD (diagnosed by any
criteria) during antipsychotic treatment, and for whom the dose
of antipsychotic medication had been stable for at least one month
(the same applied for people free of antipsychotics).
Types of interventions
Calcium channel blockers (e.g.diltiazem, nifedipine, nimodipine,
verapamil, flunarizine) at any dose compared with placebo or no
intervention. For the 2015 update, a post hoc decisionwasmade to
also include studies evaluating calcium channel blockers compared
with any other intervention for the treatment of TD.
Types of outcome measures
We planned to group all outcomes into time periods: short term
(less than six weeks), medium term (between six weeks and six
months) and long term (over six months). We defined clinical
efficacy as an improvement in the symptoms of TD of more than
50%, on any scale, after at least six weeks of intervention.
Primary outcomes
1. Tardive dyskinesia (TD)
i) No clinically important improvement in the
symptoms of individuals, defined as more than 50%
improvement on any TD scale - any time period.
2. Adverse effects
i) No clinically significant extrapyramidal adverse effects
- any time period.
Secondary outcomes
1. Tardive dyskinesia (TD)
i) Any improvement in the symptoms of participants on
any TD scale, as opposed to no improvement.
ii) Deterioration in the symptoms of participants,
defined as any deleterious change on any TD scale.
iii) Mean change in severity of TD during the trial period.
iv) Mean difference (MD) in severity of TD at the end of
the trial.
2. General mental state changes
i) Deterioration in general psychiatric symptoms (such
as delusions and hallucinations) defined as any deleterious
change on any scale.
ii) MD in severity of psychiatric symptoms at the end of
the trial.
3. Acceptability of the treatment
i) Acceptability of the intervention to the participant
group as measured by numbers of people leaving the trial early.
4. Adverse effects
i) Use of any anti-parkinsonism drugs.
ii) Mean score/change in extrapyramidal adverse effects.
iii) Acute dystonia.
5. Other adverse effects, general and specific
6. Hospital and service utilisation outcomes
i) Hospital admission.
ii) Mean change in days in hospital.
iii) Improvement in hospital status (e.g. change from
formal to informal admission status, use of seclusion, level of
observation).
7. Economic outcomes
i) Mean change in total cost of medical and mental
health care.
ii) Total indirect and direct costs.
8. Social confidence, social inclusion, social networks or
personalised quality of life measures
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i) No significant change in social confidence, social
inclusion, social networks or personalised quality of life measures.
ii) Mean score/change in social confidence, social
inclusion, social networks or personalised quality of life measures.
9. Behaviour
i) Clinically significant agitation.
ii) Use of adjunctive medication for sedation.
iii) Aggression to self or others.
10. Cognitive state
i) No clinically important change.
ii) No change, general and specific.
’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2008) and GRADEpro to import data from Review Manager 5
(RevMan 2014) to create ’Summary of findings’ tables. These ta-
bles provide outcome-specific information concerning the overall
quality of evidence from each included study in the comparison,
themagnitude of effect of the interventions examined and the sum
of the available data on all outcomes we rated as important to pa-
tient care and decision making. This summary was used to guide
our conclusions and recommendations. We selected the following
main outcomes for inclusion in the ’Summary of findings’ table.
1. Tardive dyskinesia.
i) Not improved to a clinically important extent.
ii) Deteriorated.
2. Mental state.
i) Deterioration.
3. Adverse effect.
i) Any adverse event.
ii) Adverse effects: no clinically significant extrapyramidal
adverse effects.
4. Acceptability of treatment.
i) Leaving the study early.
5. Social confidence, social inclusion, social networks or
personalised quality of life measures.*
i) No significant change in social confidence, social
inclusion, social networks or personalised quality of life measures
for either recipients of care or carers.
* Outcome designated important to patients. We wished to add
perspectives from people’s personal experience with TD to the
research agenda. A consultation with service users was planned
where the previously published version of a review in theCochrane
TD series (Soares-Weiser 2011; Table 1) and a lay overview of the
review gave the foundation for the discussions. The session was
planned to provide time to reflect on current research on TD and
consider gaps in knowledge. The report is not completed but we
will add a link to it within this review but have added one figure
showing service-user expression of frustration concerning this ne-
glected area of research (Figure 2). Informed by the results of the
consultation, for this review, we included outcomes important to
service users to the Summary of findings for themain comparison.
Figure 2. Message from one of the participants of the public and patient involvement consultation of service
user perspectives on tardive dyskinesia research.
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Search methods for identification of studies
Electronic searches
The 2015 review update was carried out in parallel with updating
eight other Cochrane TD reviews, see Table 1 for details. The
search covered all nine TD reviews.
1. Cochrane Schizophrenia Group’s Register
We searched Cochrane Schizophrenia Group’s Study-Based Reg-
ister of Trials on July 16, 2015 and April 26, 2017 using the fol-
lowing string:*Tardive Dyskinesia* in Healthcare Condition Field of
Study. In such a study-based register, searching the major concept
retrieves all the synonym keywords and relevant studies because all
the studies have already been organised based on their interven-
tions and linked to the relevant topics.The Cochrane Schizophre-
nia Group’s Register of Trials is compiled by systematic searches
of major resources (including AMED, BIOSIS, CINAHL, Em-
base, MEDLINE, PsycINFO, PubMed, and registries of clinical
trials) and their monthly updates, handsearches, grey literature,
and conference proceedings (see Group s Module). There is no
language, date, document type, or publication status limitations
for inclusion of records into the register.
2. Details of previous electronic searches
See Appendix 1.
Searching other resources
1. Reference searching
We searched the reference lists of all included studies to identify
more studies.
2. Personal contact
Where necessary, we contacted the first author of each included
study for information regarding unpublished trials. We noted the
outcome of this contact in the ’Characteristics of included studies’
or ’Characteristics of excluded studies’ tables.
Data collection and analysis
Selection of studies
For the 2015 and 2017 searches, two reviewers, RA and AG (see
Acknowledgements) inspected all abstracts of studies identified to
identify potentially relevant reports. We resolved disagreement by
discussion, or where there was still doubt, we acquired the full
article for further inspection. We acquired the full articles of rele-
vant reports/abstracts meeting initial criteria for reassessment and
carefully inspected for a final decision on inclusion (see Criteria
for considering studies for this review). The review authors were
not blinded to the names of the authors, institutions or journal of
publication. Where difficulties or disputes arose, we asked a third
review author (HB) for help and had it been impossible to decide,
we planned to add these studies to those awaiting assessment and
contacted the authors of the papers for clarification.
Study selection was performed by KS-W and John McGrath for
the initial version of this review (Soares 2001), by JR for the
2003 update (Soares-Weiser 2004), and by AE and HD (see
Acknowledgements) for the 2011 update (Essali 2011).
Data extraction and management
1. Extraction
For the 2015 update, two review authors (HB and RA) extracted
data from all included studies. We discussed any disagreement
and documented decisions, requesting that a third review author
(KSW) helped clarify issues and we documented these final de-
cisions. We extracted data presented only in graphs and figures
whenever possible, but included only if two review authors inde-
pendently had the same result. We attempted to contact authors
through an open-ended request to obtain missing information or
for clarification whenever necessary. If studies were multi-centre,
where possible, we extracted data relevant to each component cen-
tre separately.
2. Management
2.1. Forms
For the 2015 update, we extracted data on to simple forms. Ex-
tracted data are available here with a link to the original source
PDF for each item (last accessed 1 August 2017).
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2.2. Scale-derived data
We included continuous data from rating scales only if:
1. the psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
and
2. the measuring instrument was not written or modified by
one of the trialists for that particular trial; and
3. the measuring instrument was either a self-report or
completed by an independent rater or relative (not the therapist).
2.3. Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. However, calculation of change needs two assessments
(baseline and endpoint) which can be difficult in unstable and
difficult-to-measure conditions such as schizophrenia.We decided
primarily to use endpoint data and only use change data if the for-
mer were not available. We combined endpoint and change data
in the analysis as we preferred to use MD rather than standard-
ised mean differences (SMD) throughout (Higgins 2011; Chapter
9.4.5.2).
2.4. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards
to relevant data before inclusion.
Note: we entered data from studies of at least 200 participants
in the analysis, because skewed data pose less of a problem in
large studies. We also entered all relevant change data as when
continuous data are presented on a scale that includes a possibility
of negative values (such as change data), it is difficult to determine
whether data are skewed or not.
For endpoint data from studies with fewer than 200 participants:
1. when a scale started from the finite number zero, we
subtracted the lowest possible value from the mean, and divided
this by the standard deviation (SD). If this value was lower than
1, it strongly suggests a skew and we excluded these data. If this
ratio was higher than 1 but below 2, there is suggestion of skew.
We entered these data and tested whether their inclusion or
exclusion change the results substantially. Finally, if the ratio was
larger than 2, we included these data, because skew is less likely (
Altman 1996; Higgins 2011).
2. if a scale started from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS) (Kay 1986)), which can
have values from 30 to 210), we modified the calculation
described above to take the scale starting point into account. In
these cases, skew is present if 2 SD > (S - Smin), where S is the
mean score and Smin is the minimum score.
2.5. Common measure
Where relevant, to facilitate comparison between trials, we con-
verted variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6. Conversion of continuous to binary
Where possible, we converted continuous outcome measures to
dichotomous data. This was done by identifying cut-off points on
rating scales and dividing participants accordingly into ’clinically
improved’ or ’not clinically improved’. It is generally assumed that
if there is a 50% reduction in a scale-derived score such as the Brief
Psychiatric Rating Scale (BPRS; Overall 1962) or PANSS (Kay
1986), this can be considered as a clinically significant response
(Leucht 2005a; Leucht 2005b). If data based on these thresholds
were not available, we used the primary cut-off presented by the
original authors.
2.7. Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
calcium channel blockers. Where keeping to this made it impos-
sible to avoid outcome titles with clumsy double-negatives (e.g.
’Not un-improved’) we presented data where the left of the line
indicated an unfavourable outcome and noted this in the relevant
graphs.
Assessment of risk of bias in included studies
Two review authors (RA and HB) independently assessed risk of
bias within the included studies using criteria described in the
Cochrane Handbook for Systematic Reviews of Interventions to assess
trial quality (Higgins 2011). This set of criteria is based on evidence
of associations between overestimate of effect and high risk of bias
of the article such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
If the raters disagreed, we made the final rating by consensus, with
the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of
trials were provided, we contacted authors of the studies to obtain
further information. If non-concurrence occurred, we reported
this.
We noted the level of risk of bias in the text of the review and
in Figure 3; Figure 4; and Summary of findings for the main
comparison.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
11Calcium channel blockers for antipsychotic-induced tardive dyskinesia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Measures of treatment effect
1. Binary data
For binary outcomes, we planned to calculate a standard estima-
tion of the risk ratio (RR) and its 95% confidence interval (CI).
It has been shown that RR is more intuitive (Boissel 1999) than
odds ratios (ORs) and that ORs tend to be interpreted as RR by
clinicians (Deeks 2000).
2. Continuous data
For continuous outcomes, we planned to estimate MD between
groups. We preferred not to calculate effect size measures SMD.
However, had scales of very considerable similarity been used, we
would have presumed there was a small difference inmeasurement,
and we would have calculated effect size and transformed the effect
back to the units of one or more of the specific instruments.
Unit of analysis issues
1. Cross-over studies
This area of research commonly uses cross-over studies where one
person is randomly allocated the treatment only to be crossed
over to receive the comparison after a designated time. Often a
period of drug free ’washout’ is used between the interventions to
try and ensure that no carry-over effects of the first intervention
remain before commencing the second treatment. The statistical
methods for including cross-over studies in meta-analyses have
developed considerably (Curtin 2002a; Curtin 2002b; Curtin
2002c; Elbourne 2002).
However, there is a clinical problem. Antipsychotic-induced TD
seems to result from the prolonged blockade of specific receptor
sites in the brain resulting in changes (dopamine receptor hyper-
sensitivity) that develop over long periods of time and are likely
to be slow to reverse. Should an experimental intervention suc-
cessfully begin the downgrading of the dopamine receptor sites, it
seems probable that this downgrading could take a long time to
start and, once started, be equally slow to stop. Therefore, it seems
entirely feasible that the drugs could have an effect even after they
had been expelled from the body within the washout period. In
addition, cross-over studies usually assume that the investigated
condition should be stable (Elbourne 2002), and TD is not a sta-
ble condition. Consequently, we only used data of the first phase
of cross-over studies in this review because of the nature of the
condition under review.
2. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Authors often fail to account for
intraclass correlation in clustered studies, leading to a ’unit of anal-
ysis’ error (Divine 1992), whereby P values are spuriously low, CIs
unduly narrow and statistical significance overestimated, causing
type I errors (Bland 1997; Gulliford 1999). We planned to deal
with clustering in this review as described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011; Section
16.3).
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, we would
have presented the additional relevant treatment arms in compar-
isons. We would not have reproduced irrelevant additional treat-
ment arms.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them in analyses. However, if more than 50% of
participants in one arm of a study were lost, but the total loss was
less than 50%, we addressed this within the ’Summary of findings’
table by downgrading quality. We also downgraded quality within
the ’Summary of findings’ table should loss be 25% to 50% in
total.
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we pre-
sented data on a ’once-randomised-always-analyse’ basis (an inten-
tion-to-treat (ITT) analysis). We assumed all participants leaving
the study early had no improvement. We undertook a sensitivity
analysis testing how prone the primary outcomes were to change
by comparing data only from people who completed the study to
that point to the ITT analysis using the above assumptions.
3. Continuous
3.1. Attrition
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We reported and used data where attrition for a continuous out-
come was between 0% and 50%, and data only from people who
completed the study to that point were reported.
3.2. Standard deviations
If SDs were not reported, we first tried to obtain the missing
values from the authors. If not available, where there were missing
measures of variance for continuous data, but an exact standard
error (SE) and CIs available for group means, and either ’p’ value
or ’t’ value available for differences in mean, we calculated them
according to the rules described in the Cochrane Handbook for
Systemic reviews of Interventions (Higgins 2011): when only the SE
is reported, SDs are calculated by the formula SD = SE * square
root (n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for
Systemic reviews of Interventions (Higgins 2011) present detailed
formulae for estimating SDs fromP values, t or F values, CI, ranges
or other statistics. If these formulae did not apply, we calculated
the SDs according to a validated imputation method which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. We nevertheless examined the validity of
the imputations in a sensitivity analysis excluding imputed values.
3.3. Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers, others use the method of last ob-
servation carried forward (LOCF), while more recently methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and differences in the reasons for leaving the stud-
ies early between groups is often the core problem in randomised
schizophrenia trials. Therefore, we did not exclude studies based
on the statistical approach used. However, we preferred to use the
more sophisticated approaches (e.g. MMRM or multiple-imputa-
tion) and only presented completer analyses if some type of ITT
data were not available. Moreover, we addressed this issue in the
item “incomplete outcome data” of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise and discussed in the text if they arose.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise and discussed in the text if they arose.
3. Statistical heterogeneity
3.1. Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2. Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 method alongside theChi2 ’P’ value. The I2 statistic provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
the I2 statistic depends on the magnitude and direction of effects
and the strength of evidence for heterogeneity (e.g. ’P’ value from
Chi2 test, or a CI for I2 statistic). An I2 statistic estimate of 50%
or greater accompanied by a statistically significant Chi2 statistic
can be interpreted as evidence of substantial levels of heterogene-
ity (Section 9.5.2 Cochrane Handbook for Systematic Reviews of In-
tervention; Higgins 2011). We explored and discussed in the text
potential reasons for substantial levels of heterogeneity (Subgroup
analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results. These
are described in Section 10.1 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We tried to locate
protocols of included randomised trials. Where the protocol was
available, we compared outcomes in the protocol and in the pub-
lished report. Where the protocol was not available, we compared
outcomes listed in the methods section of the trial report with the
reported results.
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2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We did not
plan to use funnel plots for outcomes where there were 10 or fewer
studies, or where all studies were of similar sizes. In other cases,
where funnel plots were possible, we planned to seek statistical
advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies
which are often the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
Therefore, we intended to use the fixed-effect model for all anal-
yses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1. Calcium channel blocker
As calcium channel blockers may have differential effects on an-
tipsychotic-induced TD, we performed a subgroup analysis to
compare the effects of different calcium channel blockers. We pro-
posed to undertake comparisons only for primary outcomes to
minimise the risk of multiple comparisons.
1.2. Recent-onset tardive dyskinesia
We anticipated a subgroup analysis to test the hypothesis that the
use of calcium channel blockers is most effective for people with
recent-onset TD (less than five years). We had hoped to present
data for this subgroup for the primary outcomes.
2. Investigation of heterogeneity
We would have reported inconsistency if it appeared high. First,
we would have investigated whether data had been entered cor-
rectly. Second, if data had been entered correctly, we would have
visually inspected the graph and removed outlying studies to see
if homogeneity was restored. Should this have occurred with no
more than 10% of the data being excluded, we would have pre-
sented the data. If not, we would have pooled the data and dis-
cussed the issues.
If unanticipated clinical ormethodological heterogeneity had been
obvious, we would have simply stated hypotheses regarding these
for future reviews or updated versions of this review. We prespec-
ified no characteristics of studies that may be associated with het-
erogeneity except quality of trial method. If no clear association
could have been shown by sorting studies by the methodological
quality, we would have performed a random-effects meta-analysis.
Should another characteristic of the studies have been highlighted
by the investigation of heterogeneity, perhaps some clinical hetero-
geneity not hitherto predicted or plausible causes of heterogene-
ity, we would have discussed these post hoc reasons and analysed
and presented the data. However, should the heterogeneity have
been substantially unaffected by use of random-effects meta-anal-
ysis and no other reasons for the heterogeneity have been clear, we
would have presented the final data without a meta-analysis.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we would have included these studies and if there was
no substantive difference when the implied randomised studies
were added to those with better description of randomisation, then
we would have used all the data from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we would have compared the
findings of the primary outcomes when we used our assumption
compared only with completer data. If there had been a substantial
difference, we would have reported results and discussed them but
continued to employ our assumption.
3. Duration of follow-up
We would have undertaken a third sensitivity analysis to com-
pare primary outcomes between short-term (less than six weeks),
medium-term (between six weeks and six months) and long-term
(over six months) trials.
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R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
The original searches identified thousands of citations. On in-
spection, very few of these studies were relevant to this review.
The 2003 update search benefited from the legacy of work that
had gone before and only found 15 studies not identified by the
original search. Only nine of these were in any way relevant but
all were excluded. The 2010 update search found no additional
studies. The 2013 update search identified 38 studies, of which
16 had already been considered for this review. All the remaining
22 studies were excluded.
The searches up to 2017 retrieved 704 references for 344 studies,
see Figure 5 for study flow diagram. The 2015 and 2017 update
searches were part of an update of nineCochrane reviews, see Table
1.
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Figure 5. Study flow diagram (2015 and 2017 update search results only).
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From the 2015 search, we excluded irrelevant references and
screened titles and abstracts.We obtained full texts of 45 references
(42 studies). One of these reports was a new study to this review
in Chinese (Zeng 1994). Another two studies were previously ex-
cluded because all data were unusable (Loonen 1992; Schwartz
1997); however, we did find some useable data and could include
them.Three studies are now included in this review (Loonen 1992;
Schwartz 1997; Zeng 1994).
The 2017 search found 8 records (5 studies). Editorial base of
Cochrane Schizophrenia screened these records andnonew studies
were relevant to this review. They could be relevant to another
reviews in this series of TD reviews (see Table 1), and have been
put into awaiting assessment of Soares-Weiser 2003.
Included studies
Overall the review now includes three studies with 47 participants
published between 1992 and 1997.
1. Methods
All studies were stated to be randomised and double blind.
For further details, see Allocation (selection bias) and Blinding
(performance bias and detection bias) sections for further details.
2. Design
All three included studies presented a cross-over design with two
periods. We had considered this as likely when embarking on the
review and have used only the data from the first phase for the
reasons outlined above in the Unit of analysis issues section.
3. Duration
All studies were of short duration (less than 10 weeks) and did
not perform any long-term follow-ups. The study by Zeng 1994
employed a washout period of two weeks.
4. Participants
Participants, now totalling 47 people, were mostly men in their
50s, with diagnoses of various chronic psychiatric disorders, but
mainly schizophrenia. All had antipsychotic-induced TD diag-
nosed using either Schooler and Kane’s research diagnostic criteria
or the Abnormal Involuntary Movement Scale (AIMS). The num-
ber of participants in the three included studies were 14 (Zeng
1994), 15 (Schwartz 1997), and 18 (Loonen 1992).
5. Setting
Trials were conducted in hospital. The studies themselves were
from the USA (Schwartz 1997), China (Zeng 1994), and the
Netherlands (Loonen 1992).
6. Interventions
6.1. Calcium channel blockers
6.1.1. Diltiazem hydrochloride
Loonen 1992 used diltiazem hydrochloride 60 mg, twice per day.
6.1.2. Nifedipine
Schwartz 1997 used nifedipine 60 mg per day.
6.1.3. Flunarizine
Zeng 1994 used flunarizine but did not specify the dose, reporting
that participants took one capsule twice per day.
6.2. Comparison group
All studies used a placebo as a comparison group, with no fur-
ther details given. None of the included studies compared calcium
channel blockers to another active intervention.
Participants remained on schizophrenia treatment antipsychotic
medication during the trials.
7. Outcomes
7.1. General
Some outcomes were presented in graphs, inexact P values of dif-
ferences, or a statement of significant or non-significant difference.
This made it impossible to acquire raw data for synthesis. Some
continuous outcomes could not be extracted due to missing num-
ber of participants or missing means, SDs or SEs. All included
studies used the LOCF strategy for the ITT analysis of dichoto-
mous data.
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7.2. Scales used to measure the tardive dyskinesia symptoms
Wehave showndetails of the scales that providedusable data below.
We have provided reasons for exclusions of data under ’Outcomes’
in the Characteristics of included studies table.
7.2.1. Abnormal Involuntary Movement Scale
The AIMS is a 12-item scale consisting of a standardised examina-
tion followedby questions rating the orofacial, extremity and trunk
movements, as well as three global measurements (Guy 1976).
Each of these 10 items can be scored from 0 (none) to 4 (severe).
Two additional items assess the dental status. The AIMS ranges
from 0 to 40, with higher scores indicating greater severity.
7.3. Scales used to measure cognitive functioning
7.3.1. Dementia Rating Scale
The Dementia Rating Scale (DRS) is a five-item scale designed
to assess level of cognitive functioning for people with brain dys-
function (Mattis 1988). The five scales are: attention, initiation-
perseveration, construction, conceptualisation and memory.
Excluded studies
There were 39 excluded studies. Eleven studies were not ran-
domised. We excluded 24 studies because participants had
schizophrenia or other mental conditions but not TD. One ex-
cluded study did not report data separately for the included mi-
nority with TD (Suddath 1991). After many years of unsuccess-
ful attempts to contact authors for further details, we have also
excluded a further four randomised studies which reported no
usable data (Leys 1988; Rzewuska 1995; Fay-McCarthy 1997a;
Fay-McCarthy 1997b), or did not report data separately for the
first phase before crossing over to the next treatment (Yamada
1996).
Studies awaiting assessment
We found no studies awaiting assessment.
Ongoing studies
We found no ongoing studies.
Risk of bias in included studies
Refer to Figure 3 and Figure 4 for graphical overviews of the risk
of bias in the included studies.
Allocation
Only Loonen 1992 provided explicit details about the randomi-
sation sequence generation. The other two studies did not explain
how allocation was achieved other than using the word “random-
ized.” Zeng 1994 reported a centrally controlled allocation while
the other two studies did not provide explicit details.
Blinding
Although all studies were conducted on a double-blind basis,
Schwartz 1997 did not explicitly describe how this was under-
taken. No study described the blinding of outcome assessors in
detail or tested the blindness of raters, clinicians and trial partici-
pants.
Incomplete outcome data
Two studieswere at high risk of attrition bias because they excluded
participants who dropped out of the study from the analysis (
Loonen 1992; Schwartz 1997). All participants in the study by
Zeng 1994 completed the trial.
Selective reporting
The majority of data in this review originated from published
reports. Expected outcomes (impact on TD symptoms) were re-
ported by two of the three trials (Loonen 1992 and Zeng 1994)
but only Zeng 1994 reported results of all outcomes listed in the
methods section fully . Loonen 1992 and Schwartz 1997 did not
fully report outcomes that were measured during the study and
were rated at high risk of reporting bias. Attempts to contact au-
thors of trials for additional data were unsuccessful.
Other potential sources of bias
All studies had small or very small sample sizes, and used a cross-
over design. There was very little information reported on which
to base further concerns regarding risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Calcium
channel blocking drugs for people with antipsychotic-induced
tardive dyskinesia
1. Comparison 1. Calcium channel blockers versus
placebo
1.1. Tardive dyskinesia: AIMS endpoint score
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We had chosen ’any improvement in TD symptoms of more than
50% on any TD scale - any time period’ as a primary outcome. No
data found in the included trials fit this exactly, so only endpoint
scores of the AIMS were pooled.
TD symptoms were measured on the continuous AIMS scale (see
Section 7.2 Scales used to measure the TD symptoms). There was
no benefit of calcium channel blockers when compared to placebo
after three to four weeks (2 RCTs, n = 37; MD -0.71, CI -2.68 to
1.26; very low quality evidence; I2 = 0%; Analysis 1.1).
1.2. Adverse effects: any adverse effects (short term)
One study reported no adverse effects during the study period as a
result of flunarizine or placebo (1 RCT, n = 20; RR not estimable;
very low quality evidence; Analysis 1.2).
1.3. Mental state: deterioration (short term)
One trial found that no participant in diltiazem hydrochloride or
placebo groups deteriorated during the study (1 RCT, n = 18; RR
not estimable; very low quality evidence; Analysis 1.3).
1.4. Cognitive state: mean endpoint score (DRS, low =
better)
One trial found no difference in cognitive function measured with
the DRS (see Included studies) between nifedipine and placebo
(1 RCT, n = 14; MD 2.50 CI -3.67 to 8.67; Analysis 1.4).
We did not identify any studies that reported on hospital and ser-
vice utilisation outcomes, economic outcomes, social confidence,
social inclusion, social networks, personalised quality of life, be-
haviour or that reported on leaving the study early during the first
phase before crossing over to the next treatment in cross-over stud-
ies.
1.5. Subgroup analysis
1.5.1. Calcium channel blocker
We stratified the only outcomewith data frommore thanone study
by type of calcium channel blocker. There was no heterogeneity
between flunarizine and diltiazem hydrochloride (I2 = 0%, P =
0.82; Analysis 1.1).
1.5.2. Recent-onset tardive dyskinesia
It was not possible to evaluate whether participants with recent-
onset TD responded differently to those with more established
problems, since no trial reported data for groups with different
durations of TD that could be extracted for separate analyses.
1.6. Heterogeneity
Data were homogeneous. We found no clinical, methodolog-
ical or statistical heterogeneity as described in Assessment of
heterogeneity.
1.7. Sensitivity analyses
1.7.1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. As all studies
were stated to be randomised, we did not undertake this sensitivity
analysis.
1.7.2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we intended to compare the
findings when we used our assumption compared with completer
data only. This sensitivity analysis could not be undertaken as there
were no events for any binary data outcomes.
1.7.3. Duration of follow-up
We did not undertake a sensitivity analysis investigating duration
of follow-up; included studies reported measures after very similar
duration (three or four weeks).
2. Comparison 2. Calcium channel blockers versus
any other active treatments
We found no trials reporting data on calcium channel blockers
compared with other active treatments.
D I S C U S S I O N
Summary of main results
1. The searches
This area of research does not seem to be active. The 2015 update
identified additional data, but all trials predated the year 2000.
The 2017 search identified no new data. This could be because
of reasons such as less concern with TD, or less emergence of the
problem in research-active communities because of more thought-
ful use of antipsychotic drugs and loss of faith in calcium channel
blockers as a potential treatment.
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2. Few data
Calcium channel blockers are experimental in the treatment of TD
(see Description of the intervention) and we did not expect to find
much data. Only 47 people were included in this review. For this
reason, it is likely that real, and important, effects have not been
highlighted because of the necessarily wide CIs of the findings.
Many outcomes were not measured (see Overall completeness
and applicability of evidence), including several of our prestated
outcome measures.
3. Comparison 1. Calcium channel blockers versus
placebo
3.1. Tardive dyskinesia
We found no studies that reported on no clinically important im-
provement inTD symptoms or on deterioration of TD symptoms.
Two RCTs found no significant difference on endpoint score on
the continuous AIMS scale between diltiazem or flunarizine and
placebo after three to four weeks treatment (2 RCTs, n = 37; MD
-0.71, 95% CI -2.68 to 1.26; I2 = 0%).
3.2. Adverse effects
One studywith 20 participants reported that there were no adverse
events in either study arm.
3.3. Mental state
One study with 18 participants reported that none of the partici-
pants deteriorated mentally in either study arm.
3.4. Leaving the study early
None of the included studies reported on leaving the study early
during the first phase before crossing over to the next treatment.
3.5. Social confidence, social inclusion, social networks or
personalised quality of life
This group of outcomes was selected as being of particular impor-
tance to patients for the 2015 review update following a service
user consultation. We found no studies that reported on any of
these outcomes.
Overall completeness and applicability of
evidence
1. Completeness
Only three small studies with very few useable data were included,
not sufficient to address the safety and efficacy of calcium channel
blockers in the treatment of antipsychotic-induced TD in people
with schizophrenia or other chronic mental illnesses. There was
very little evidence on TD symptoms, and no evidence on adverse
events;mental state; leaving the study early or on social confidence,
social inclusion, social networks or personalised quality of life. If
reporting had been better we may have been able to include more
data from these studies, and we may have had some data to present
from the excluded studies Leys 1988; Rzewuska 1995; Suddath
1991; and Yamada 1996.
2. Applicability
Trials were hospital based, and were on people who would be
recognisable in everyday care. Calcium channel blockers are read-
ily accessible and outcomes selected for the ’Summary of findings’
table are understandable in terms of clinical practice. Should cal-
cium channel blockers have had important effects, the findings
may well have been applicable.
Quality of the evidence
We cannot draw any robust conclusions regarding the effects, good
or bad, of calcium channel blockers on TD; only three cross-over
studies of short duration with 47 participants could be included,
which severely limited the quality of the evidence. The largest
trial randomised only 18 people. A trial of this size is unable to
detect subtle, yet important differences due to an intervention
with any confidence. In order to detect a 20% difference between
groups, probably about 150 people are needed in each arm of the
study (alpha 0.05, beta 0.8). Overall, the quality of reporting of
these trials was poor (see Figure 3). Allocation concealment was
not described, generation of the sequence was not explicit, studies
were not clearly blinded, attrition was not clearly reported for the
first cross-over phase and data were not fully reported. The small
sample size and the poor reporting means that we have very little
confidence in the effect estimates, and the true effects are likely to
be substantially different from the estimates of the effects.
Potential biases in the review process
1. Missing studies
Every effort was made to identify relevant trials. However, these
studies were all small and it is likely that we have failed to identify
other studies of limited power. It is likely that such studies would
also not be in favour of the intervention group. If they had been so,
it is more likely that they would have been published in accessible
literature. However, we do not think it likely that we have failed
to identify large relevant studies.
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2. Introducing bias
We did have foreknowledge of the past work in this area and
could have been biased in how data weremanaged or reported.We
welcome comments or criticisms. For the 2015 review update, a
new author joined the team. We re-examined excluded references
and found data that could be included (see this link for exact
source of data in the PDFs; last accessed 1 August 2017). We also
updated the ’Summary of findings’ table outcomes following a
patient consultation.
Agreements and disagreements with other
studies or reviews
The only other relevant quantitative review we know of is the
previous Cochrane Review versions (Essali 2011; Soares 2001;
Soares-Weiser 2004). This update identified three studies to in-
clude (as discussed in Results of the search and Potential biases in
the review process), but the very sparse and low-quality evidence
lead to no substantial change in the conclusions. Findings from
other similar reviews (see Table 1) suggest that TD, rather than
these interventions, is no longer a focus of research activity. How-
ever, studies evaluating treatments for TD are of importance to
people with the problem (Figure 2) and have long been ignored.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with tardive dyskinesia
Based on currently available data, this systematic review provides
no conclusions about the use of calcium channel blockers for the
treatment of antipsychotic-induced tardive dyskinesia (TD) - ex-
cept that they are purely experimental treatments. People with
TD should only take such experimental interventions, with their
potential to do harm, within the context of well-designed ran-
domised controlled trials.
2. For clinicians
In the absence of reliable evidence, clinicians prescribing calcium
channel blockers for people with TD must balance the possible
benefits against the potential adverse effects of the treatment. Cal-
cium channel blockers lower people’s blood pressure andmay even
cause symptoms of TD to increase. These drugs should only be
used in a situation where their effects are closely monitored, that
is, within randomised trials designed to inform practice.
3. For policy makers
There is no indication that calcium channel blockers should be
introduced as part of routine treatment policy for people with
TD. However, policy makers could specify that such experimental
treatments only be used within the context of a trial.
4. For funders of research
Calcium channel blockers for TDwould not seem to be the first set
of compounds to choose to investigate within randomised stud-
ies. However, if a funding agency was intent on supporting such
research, stipulation of the design outlined under ’Further trials’
in Implications for research and in Table 2 and reporting issues
would seem prudent.
Implications for research
1. Reporting
Two out of three of the included studies in this review preceded the
CONSORT statement (Begg 1996; Moher 2001), so the quality
of data reporting might be expected to be lower than at present.
Future studies should rigorously apply the standards of reporting
as outlined in CONSORT and also make all data freely available.
2. Further reviews
As is usual with systematic reviews, several studies were identified
that could be added into existing reviews or suggested comparisons
for new reviews of the future. These are listed in Table 3.
3. Further trials
Because calcium channel blockers have dopamine-blocking prop-
erties, this group of drugs could be implicated in the appearance of
TD. This makes the necessity of further trials debatable. However,
if further randomised trials are being planned, then inclusion of
the following design elements would be helpful.
1. Use of a parallel-group, placebo-controlled design. This has
benefits over cross-over studies. Trialists find it difficult to
identify people with both TD and schizophrenia to participate in
trials. Randomised cross-over design is used in the hope of
improving the power of the study to find outcomes of interest.
This design initially asks participants to be randomised to one of
the experimental interventions, and then, at a prespecified time,
to be crossed over to the other treatment. Conditions with a
more stable time course than TD are better suited for cross-over
studies (Fleiss 1984). Further difficulties are related to the carry-
over effect. Unless cross-over studies include a mid-study
washout period (where the person is free of treatment before
starting the next arm of the study), any effect of the first
intervention may continue into the second half placebo arm of
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the trial (the ’carry-over effect’). Also, carry-over may involve the
regrowth or retreat of neuroreceptors. This slow rebalancing, if
started, could continue long after all traces of intervention drugs
are gone, so physiological half life of the experimental treatment
may not be the only variable to consider when thinking through
the issues of carry-over. TD is also an unstable condition and
people with TD may not remain compliant with medication. All
these factors make the arguments for not using cross-over
methodology strong, despite the initial attraction (Armitage
1991; Fleiss 1984; Pocock 1983).
2. Trials which extend for at least six weeks.
3. Sample size which is sufficiently large to avoid false
conclusions about effectiveness of intervention.
A suggested design is outlined in Table 2.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Loonen 1992
Methods Allocation: “random permuted block,” allocation not described
Blindness: “double-blind to placebo tablets which looked identically.”
Duration: 6 weeks (3 weeks then crossed over for another 3 weeks)
Design: cross-over.
Setting: inpatients, the Netherlands.
Raters: not reported.
Participants Diagnosis: DSM-III-R psychiatric diagnoses (schizophrenia, personality and develop-
ment disorders) and clinical diagnosis of TD
Duration of TD: > 6 months.
n = 18*.
Sex: 11 women, 6 men (among completers).
Age: mean (SD): 57.2 (9.30) years; range 37-69 years.
Interventions 1. Diltiazem hydrochloride: dose 60 mg 4 times daily (n = 9).
2. Placebo (n = 9).
All stable on antipsychotics for ≥ 3 weeks before entry and during the trial
Concomitant medication: all stable for ≥ 3 weeks before entry and during the trial:
anticholinergics (n = 9), benzodiazepines (n = 2), anticonvulsants (n = 2) and diuretics
(n = 2)
Outcomes TD symptoms: AIMS.
Mental state: deterioration (CGI).
Notes Sponsorship source: not reported.
*2 participants were non-compliant and were replaced.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants who entered the study ran-
domly allocated to treatment group 1 or 2
by random permuted block technique with
a block size of 2. Random number gen-
erator method to select random permuted
blocks not reported, but likely computer
generated
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind to placebo tablets which
looked identically;” “The double-blind
code was not broken until the last patient
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Loonen 1992 (Continued)
had terminated.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details of blinding of assessors not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Not intention-to-treat. “Eighteen patients
with TD entered the study. During the
study, three subjects terminated prema-
turely. Two of them showed an obvious
lack of compliance unrelated to trial med-
ication; these subjects were replaced. One
patient developed atrial fibrillation, which
required digitalization. When the double-
blind code of this patient was broken, it ap-
peared that the atrial fibrillation had started
during the placebo period. Thus, the num-
ber of subjects who completed the study
was 17.”
Unclear when the non-compliant partici-
pants were replaced (period 1 or 2) and
which group they were randomised to
Selective reporting (reporting bias) High risk Full trial report available with all outcomes
reported but most outcomes not reported
for the first period before cross-over
Other bias Unclear risk Unable to assess baseline differences - char-
acteristics were reported per participant but
not per group, therefore, unclear if there
were confounding variables that may have
led to bias
Schwartz 1997
Methods Allocation: “random assignment.”
Blindness: “double-blind.”
Duration: 8 weeks (4 weeks then crossed over for another 4 weeks)
Design: cross-over.
Setting: not described, USA.
Raters: not described.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-lll-R). Research criteria for
TD: “moderate” abnormal involuntary movements in ≥ 1 body areas or at least a rating
of “mild” movements in ≥ 2 body areas on the AIMS
Duration of TD: not reported.
n = 15.
Sex: 14 men, 1 woman.
Age: mean 45.7 years; range 36-58 years.
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Schwartz 1997 (Continued)
Interventions 1. Nifedipine: 60 mg/day for 4 weeks (n = 9).
2. Placebo (n = 5).
All stable on antipsychotics, captopril mean dose 1405 mg (range 150-6250 mg) for ≥
1 month before entry and during the trial
Concomitant medication: not reported.
Outcomes Cognitive changes (DRS) (digitised and extracted from figure)
Unable to use:
Mental state: BPRS, SANS (data not fully reported).
Adverse effects: AIMS, SAS, BAS, Chouinard and Ross-Chouinard Scale (data not fully
reported)
Notes Sponsorship source: support from theNational Institute ofMentalHealth (to last author)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “random assignment;” further details were
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment details not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind;” further details were not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind;” further details were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Not intention-to-treat. “The data for one
patient from one test phase was missing;
therefore, there were 14 patients included
in the analysis of data.”
Selective reporting (reporting bias) High risk Several outcomes not fully reported.
Other bias Low risk “statistical comparisons showed that pa-
tients in the two drug orders did not differ
from each other in terms of age, severity of
initial psychiatric symptoms or abnormal
movements, dose of antipsychotic medica-
tion, or duration of illness.”
The study seemed free of other sources of
bias.
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Zeng 1994
Methods Allocation: “random,” allocation properly described.
Blindness: described and adequate.
Duration: 10 weeks (4 weeks, 2-week washout then crossed over for another 4 weeks)
Design: cross-over.
Setting: Institute of Mental Health Institute of Jining, Shan dong, China
Raters: not described.
Participants Diagnosis: people with schizophrenia and antipsychotic-inducedTD; AIMS≥ 5; normal
physical and laboratory examinations
Duration of TD: mean (SD) 5.9 (3.4) years.
n = 14.
Sex: 11 male, 3 female.
Age: mean (SD) 31 (9) years.
Stable antipsychotic dose for ≥ 5 months before study commencement. All participants
received stable nerve blockade (such as phenothiazines, haloperidol, sulpiride). Other
concomitant medication not reported
Interventions 1. Flunarizine: at first phase, 1 capsule, twice per day for 4 weeks (n = 10).
2. Placebo: at first phase, 1 capsule, twice per day for 4 weeks (n = 10).
Outcomes TD symptoms: AIMS.
Adverse events: any adverse events.
Notes Sponsorship source: not reported.
Chinese language publication; assessed and data extracted by Sai Zhao
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “cross over randomised trial;” further de-
tails not reported.
Allocation concealment (selection bias) Low risk Pharmacy-controlled central allocation:
“the interventions were coded as interven-
tion A or B by the researcher in the phar-
macy.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double blind study, the interventions were
coded as intervention A or B by the re-
searcher in pharmacy;” “Participants and
personnel did not know the allocation re-
sult. The two drugs contained in capsules
with the same appearance.”
Blinding of participants and key study per-
sonnel ensured.
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Zeng 1994 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants competed study.
Selective reporting (reporting bias) Low risk Authors reported all measured outcomes.
Other bias Low risk No further concerns.
AIMS: Abnormal Involuntary Movement Scale; BAS: ; BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression; DRS:
Dementia Rating Scale; DSM-III-R: Diagnostic & Statistical Manual of Mental Disorders - 3rd Edition Revised; n: number of
participants; SANS: Scale for the Assessment of Negative Symptoms; SAS: Simpson-Angus Extrapyramidal Signs Scale; SD: standard
deviation; TD: tardive dyskinesia.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adler 1988 Allocation: not described as randomised or double blind, only raters were described as blinded
Alexander 1978 Allocation: not randomised.
Alexander 1979 Allocation: not randomised.
Athanassenas 1983 Allocation: not randomised.
Bisol 2008 Allocation: randomised.
Participants: people with chronic DSM-IV-defined schizophrenia, not with TD
Interventions: flunarizine compared with haloperidol.
Brambilla 1992 Allocation: not randomised.
Carman 1979 Allocation: “double blind.”
Participants: people with psychosis, not with TD.
Interventions: dihydrotachysterol.
Dose 1991 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: carbamazepine vs valproate vs beclamide vs placebo
Duncan 1990 Allocation: not randomised, cohort study.
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(Continued)
Egan 2013 Allocation: randomised.
Participants: people with schizophrenia, acutely ill, not with TD
Interventions: MK-8998 vs olanzapine vs placebo.
Ehrenreich 2007 Allocation: randomised.
Participants: men with chronic schizophrenia, not with TD.
Interventions: recombinant human erythropoietin vs placebo.
Falk 1988 Allocation: not randomised, case report.
Fay-McCarthy 1997a Allocation: “random order.”
Participants: people with schizophrenia, not with TD.
Interventions: nifedipine vs placebo.
Outcomes: no usable data.
Fay-McCarthy 1997b Allocation: unclear, cross-over study.
Participants: people with schizophrenia, not with TD.
Interventions: nifedipine vs placebo.
Outcomes: no usable data (authors contacted, no reply).
Grebb 1986 Allocation: not randomised, case report.
Huang 2004 Allocation: randomised.
Participants: people with senility with first-episode schizophrenia, not with TD
Interventions: perphenazine vs perphenazine + nimodipine.
Janicak 1998 Allocation: randomised.
Participants: people with mania, not with TD.
Interventions: verapamil vs placebo.
Krupitsky 1999 Allocation: randomised.
Participants: healthy people, not with TD.
Interventions: nimodipine vs ketamine vs placebo.
Lara 2009 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: flunarizine vs haloperidol.
Leys 1988 Allocation: randomised.
Participants: TD over 6 months + psychosis (n = 3), vomiting (n = 1), bipolar disorder (n = 1), behavioural
disturbances related to Alzheimer’s disease (n = 1)
Interventions: diltiazem hydrochloride vs placebo.
Outcomes: no usable outcome data reported. Contacted study author for data and no reply was received.
Consequently, we excluded this over 25-years-old study
Liebman 2010 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: tiagabine (Gabitril) vs placebo added to their antipsychotic regimen
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(Continued)
NCT00425815 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: org 24448 (ampakine) vs placebo.
NCT00469664 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: guanfacine vs placebo.
NCT00512070 Allocation: randomised.
Participants: people with schizophrenia, not with TD.
Interventions: melatonin vs placebo.
Nechifor 2004 Allocation: not randomised.
Pickar 1987 Allocation: “double blind.”
Participants: people with schizophrenia, not with TD.
Interventions: verapamil vs placebo.
Popov 2008 Allocation: not clear.
Participants: people with schizophrenia treated with haloperidol, not with TD
Intervention: nifedipine or no treatment to prevent the emergence of extrapyramidal adverse effects
Price 1986 Allocation: “double blind,” unclear if randomised, cross-over
Participants: people with schizophrenia, not with TD.
Interventions: verapamil vs haloperidol.
Ricketts 1995 Allocation: randomised.
Participants: people with mental retardation, not people with schizophrenia and TD
Ross 1987 Allocation: not randomised, case study
Rzewuska 1995 Allocation: “double blind,” not stated as randomised.
Participants: people with schizophrenia (ICD-10 diagnostic criteria) and postantipsychotic TD (n = 32)
Outcomes: BPRS, CGI, TDRS, adverse effects (physical examination, routine blood tests, ECG). Assessment
time: 0, 7, 14 and 28 days
Notes: no usable data. BPRS and TDRS results reported as % reduction
We were unable to identify up-to-date contact details of author for this 22-year-old study
Suddath 1991 Allocation: randomised, cross-over trial.
Participants: 4/10 people with TD.
Interventions: nifedipine vs placebo.
Outcomes: impossible to extract data relevant to people with TD
Contacted authors for more information but no reply received and study is > 20 years old
Wang 1995 Allocation: “double blind.”
Participants: people with sinus tachycardia induced by antipsychotic drugs, not with TD
Interventions: propranolol vs verapamil.
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(Continued)
Wei 1995 Allocation: “double blind.”
Participants: people with sinus tachycardia induced by antipsychotic drugs, not with TD
Interventions: propranolol vs verapamil.
Wei 2008 Allocation: not described.
Participants: people with schizophrenia, not with TD.
Interventions: nimodipine + sulpiride for negative symptoms of schizophrenia
Yamada 1996 Allocation: “randomly assigned,” cross-over trial.
Participants: people with schizophrenia.
Interventions: nilvadipine vs placebo.
Outcomes: no separated data available for first half of study prior to cross-over
Contacted authors for more information but no reply received and the study is > 10 years old
Yaryura 1968 Allocation: not described, unlikely to be randomised.
Participants: people with schizophrenia, not with TD.
Interventions: intravenous calcium gluconate vs sterile water
BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression;DSM-IV:Diagnostic and StatisticalManual ofMental Disorders
- 4th Edition; ECG: electrocardiogram; ICD-10: International Statistical Classification of Diseases - 10th Revision; TD: tardive
dyskinesia; TDRS: Tardive Dyskinesia Rating Scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Calcium channel blockers versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tardive dyskinesia: AIMS
endpoint score (low = better)
2 37 Mean Difference (IV, Fixed, 95% CI) -0.71 [-2.68, 1.26]
1.1 Diltiazem vs placebo -
short term
1 17 Mean Difference (IV, Fixed, 95% CI) -0.13 [-5.55, 5.29]
1.2 Flunarizine vs placebo -
short term
1 20 Mean Difference (IV, Fixed, 95% CI) -0.80 [-2.91, 1.31]
2 Adverse effects: any adverse
effects (short term)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Mental state: deterioration
(short-term)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Cognitive state: mean endpoint
score (DRS, low = better, short
term)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Calcium channel blockers versus placebo, Outcome 1 Tardive dyskinesia: AIMS
endpoint score (low = better).
Review: Calcium channel blockers for antipsychotic-induced tardive dyskinesia
Comparison: 1 Calcium channel blockers versus placebo
Outcome: 1 Tardive dyskinesia: AIMS endpoint score (low = better)
Study or subgroup
Calcium
channel
blocker Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Diltiazem vs placebo - short term
Loonen 1992 8 7.31 (5.26) 9 7.44 (6.13) 13.2 % -0.13 [ -5.55, 5.29 ]
Subtotal (95% CI) 8 9 13.2 % -0.13 [ -5.55, 5.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 Flunarizine vs placebo - short term
Zeng 1994 10 5.7 (2) 10 6.5 (2.76) 86.8 % -0.80 [ -2.91, 1.31 ]
Subtotal (95% CI) 10 10 86.8 % -0.80 [ -2.91, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 18 19 100.0 % -0.71 [ -2.68, 1.26 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
-10 -5 0 5 10
Favours Ca channel block Favours placebo
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Analysis 1.2. Comparison 1 Calcium channel blockers versus placebo, Outcome 2 Adverse effects: any
adverse effects (short term).
Review: Calcium channel blockers for antipsychotic-induced tardive dyskinesia
Comparison: 1 Calcium channel blockers versus placebo
Outcome: 2 Adverse effects: any adverse effects (short term)
Study or subgroup Flunarizine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zeng 1994 0/10 0/10 Not estimable
0.01 0.1 1 10 100
Favours flunarizine Favours placebo
Analysis 1.3. Comparison 1 Calcium channel blockers versus placebo, Outcome 3 Mental state:
deterioration (short-term).
Review: Calcium channel blockers for antipsychotic-induced tardive dyskinesia
Comparison: 1 Calcium channel blockers versus placebo
Outcome: 3 Mental state: deterioration (short-term)
Study or subgroup Diltiazem Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Loonen 1992 0/9 0/9 Not estimable
0.01 0.1 1 10 100
Favours diltiazem Favours placebo
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Analysis 1.4. Comparison 1 Calcium channel blockers versus placebo, Outcome 4 Cognitive state: mean
endpoint score (DRS, low = better, short term).
Review: Calcium channel blockers for antipsychotic-induced tardive dyskinesia
Comparison: 1 Calcium channel blockers versus placebo
Outcome: 4 Cognitive state: mean endpoint score (DRS, low = better, short term)
Study or subgroup Nifedipine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schwartz 1997 9 34 (3.6) 5 31.5 (6.51) 2.50 [ -3.67, 8.67 ]
-10 -5 0 5 10
Favours nifedipine Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Other Cochrane Reviews in the tardive dyskinesia series
Focus of review Reference
Benzodiazepines for neuroleptic-induced tardive dyskinesia Bhoopathi 2006; update to be published
Cholinergic medication for neuroleptic-induced tardive dyskine-
sia
Tammenmaa 2002; update to be published
Anticholinergic medication for neuroleptic-induced tardive dysk-
inesia
Soares 2000; update to be published
Catecholaminergic drugs for neuroleptic-induced tardive dyski-
nesia
El-Sayeh 2006; update to be published
Gamma-aminobutyric acid agonists for neuroleptic-induced tar-
dive dyskinesia
Alabed 2011; update to be published
Miscellaneous treatments* for neuroleptic-induced tardive dyski-
nesia
Soares-Weiser 2003; update to be published
Neuroleptic reduction or cessation (or both) and neuroleptics Soares-Weiser 2006; update to be published
Non-neuroleptic catecholaminergic drugs El-Sayeh 2006; update to be published
Vitamin E for neuroleptic-induced tardive dyskinesia McGrath 2001; update to be published
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* Includes botulinum toxin, endorphin, essential fatty acid, EX11582A, ganglioside, insulin, lithium, naloxone, oestrogen, periactin,
phenylalanine, paracetamol, stepholidine, tryptophan, neurosurgery and electroconvulsive therapy.
Table 2. Suggested design of study
Methods Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment
Blinding: double, tested.
Setting: anywhere.
Duration: at least 6 weeks.
Participants Diagnosis: schizophrenia, with tardive dyskinesia (clinical diagnoses, operational for random sample).
n = 300.1
Age: adults.
Sex: both.
Interventions 1. Calcium channel blocker (n = 150).
2. Placebo (n = 150).
Outcomes Tardive dyskinesia: any clinically important improvement in tardive dyskinesia, any improvement, deterioration2.
Adverse effects: no clinically significant extrapyramidal adverse effects - any time period3 , use of any antiparkinsonism
drugs, other important adverse events
Leaving the study early.
Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services
Compliance with drugs.
Economic evaluations: cost-effectiveness, cost-benefit.
General state: relapse, frequency, and intensity of minor and major exacerbations
Social confidence, social inclusion, social networks or personalised quality of life: binary measure
Distress among relatives: binary measure.
Burden on family: binary measure.
Notes 1 Powered to be able to identify a difference of about 20% between groups for primary outcome with adequate
degree of certainty
2 This simple measure can be used to target specific aspects of functioning, symptoms or attitudes
3 Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need
to have operational criteria applied if clinical impression is proved to be accurate
n: number of participants.
Table 3. Reviews suggested by excluded studies1
Study tag Intervention Suggested review
#1 #2 #3
Yaryura 1968 Calcium gluconate (iv) Placebo - Mineral supplements for schizophrenia.
Dose 1991 Carbamazepine Sodium valproate Carbamazepine for schizophrenia;
Valproate for schizophrenia.
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Table 3. Reviews suggested by excluded studies1 (Continued)
Carman 1979 Dihydrotachysterol - Vitamin D for schizophrenia.
Bisol 2008, Lara 2009 Flunarizine Haloperidol - Calcium channel blockers for schizophre-
nia.
NCT00469664 Guanfacine Placebo - Central nervous system stimulants for
schizophrenia.
NCT00512070 Melatonin - Melatonin for schizophrenia.
Egan 2013 MK-8998 Olanzapine Calcium channel blockers for schizophre-
nia; Olanzapine versus placebo for
schizophrenia
Popov 2008 Nifedipine - Calcium channel blockers for schizophre-
nia.
Fay-McCarthy 1997a -
Fay-McCarthy 1997b -
Wei 2008 Nimodipine + sulpiride -
NCT00425815 Farampator (Org
24448)
- Glutamate receptor stimulants for
schizophrenia.
Huang 2004 Nimodipine +
perphenazine
Perphenazine - Calcium channel blockers for schizophre-
nia.
Ehrenreich 2007 Recombinant human
erythropoietin
Placebo - Glycoprotein hormones for schizophre-
nia.
Liebman 2010 Tiagabine - Anticonvulsants, miscellaneous for
schizophrenia.
Price 1986 Verapamil Haloperidol - Calcium channel blockers for schizophre-
nia.
Pickar 1987 Placebo -
Wang 1995; Wei 19952 Propranolol -
1 Sorted by Intervention #1; omitting studies not relevant to people with schizophrenia.
2 People with sinus tachycardia induced by antipsychotic drugs, not with tardive dyskinesia - all other participants in studies were
people with schizophrenia but not with tardive dyskinesia.
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A P P E N D I C E S
Appendix 1. Previous searches
1. Update of 2010
We searched theCochrane SchizophreniaGroupTrialsRegister inMay 2010 using the phrase: [((*calcium* or *diltiazem* or *nifedipine*
or *nimodipine* or *verapamil*) in title or (*calcium* or *diltiazem* or *nifedipine* or *nimodipine* or *verapamil*) in title, abstract
or Index terms of REFERENCE) or (*calcium* or *diltiazem* or *nifedipine* or *nimodipine* or *verapamil*) in intervention of
STUDY]. The Schizophrenia Group’s trials register is based on regular searches of BIOSIS Inside, CENTRAL, CINAHL, Embase,
MEDLINE andPsycINFO; the handsearching of relevant journals and conference proceedings, and searches of several key grey literature
sources. A full description is given in the Group’s Module.
2. 2003 update
The Cochrane Schizophrenia Group’s trials register was searched using the phrase: [((calcium* or diltiazem* or nifedipine* or nimodip-
ine* or verapamil*) in title or (*calcium* or *diltiazem* or *nifedipine* or *nimodipine* or *verapamil) in title, abstract or Index
terms of REFERENCE) or (calcium* or diltiazem* or nifedipine* or nimodipine* or verapamil*) in intervention of STUDY]. The
Schizophrenia Group’s trials register is based on regular searches of BIOSIS Inside, CENTRAL, CINAHL, Embase, MEDLINE and
PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources. A
full description is given in the Group’s module.
3. Earlier searches
3.1 Electronic searching
Relevant randomised trialswere identified by searching several electronic databases (Biological Abstracts, theCochrane Library,Cochrane
Schizophrenia Group’s Register of trials, Embase, LILACS, MEDLINE, PsycLIT and SCISEARCH).
The Cochrane Schizophrenia Group’s Register was searched using the phrase: [calcium* or diltiazem or nifedipine or nimodipine or
verapamil or (#42 = 304 or 33)]; #42 is the ’intervention’ field within the Cochrane Schizophrenia Group’s Register and 304 and 33
are codes for the calcium channel blocking drugs within that field.
Biological Abstracts (January 1982 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase: [and ((tardive near (dyskine* or diskine*) or (abnormal near
movement* near disorder*) or (involuntar* near movement*))]. This downloaded set of reports was handsearched for possible trials and
researched, within the bibliographic package ProCite, with the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil].
Embase (January 1980 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled
trials (see Group search strategy) combined with the phrase: [and ((tardive dyskinesia in thesaurus - subheadings, prevention, drug
therapy, side effect and therapy) or (neuroleptic dyskinesia in thesaurus -all subheadings) or (tardive or dyskines*) or (movement*
or disorder*) or (abnormal or movement* or disorder*))]. This downloaded set of reports was hand searched for possible trials and
researched, within the bibliographic package ProCite, with the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil].
LILACS (January 1982 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled
trials (see Group search strategy) combined with the phrase: [and ((tardive or (dyskinesia* or diskinesia*)) or (drug induced movement
disorders in thesaurus))]. This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic
package ProCite, with the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil].
MEDLINE (January 1966 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase: [and ((movement-disorders in MeSH / explode all subheadings)
or (anti-dyskinesia-agents in MeSH / explode all subheadings) or (dyskinesia-drug-induced in MeSH / explode all subheadings) and
(psychosis inMeSH / explode all subheadings) or (schizophrenic disorders inMeSH / explode all subheadings) or (tardive near (dyskine*
or diskine*)) or (abnormal* near movement* near disorder*) or (involuntar* near movement*))]. This downloaded set of reports was
hand searched for possible trials and researched, within the bibliographic package ProCite, with the phrase [calcium* or diltiazem or
nifedipine or nimodipine or verapamil].
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PsycLIT (January 1974 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised controlled
trials (see Group search strategy) combined with the phrase: [and ((explode movement-disorders in DE) or (explode tardive-dyskinesia
in DE) or (tardive near (dyskine* or diskine*) or (abnormal* near movement* near disorder*) or (involuntar* near movement*))]. This
downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with the
phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil].
SCISEARCH - Science Citation Index database. Reports of articles that have cited these studies were inspected in order to identify
further trials.
3.2 Reference searching
The references of all identified studies were also inspected for more studies.
3.3 Personal contact
The first author of each included study was contacted for information regarding unpublished trials.
Appendix 2. Assessment of methodological quality in previous versions of this review
Themethodological quality of the trials included in previous versions of this review would have been assessed using the criteria described
in the Cochrane Collaboration Handbook (Clarke 2003) and the Jadad Scale (Jadad 1996). The former is based on the evidence of a
strong relationship between the potential for bias in the results and the allocation concealment (Schulz 1995) and is defined as below.
A. Low risk of bias (adequate allocation concealment).
B. Moderate risk of bias (unclear allocation concealment).
C. High risk of bias (inadequate allocation concealment).
The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale is made up of three items.
1. Was the study described as randomised?
2. Was the study described as double blind?
3. Was there a description of withdrawals and dropouts?
Each item receives one point if the answer is positive. In addition, a point can be deducted or added according to the description of
either the randomisation or the blinding/masking procedures.
For the purpose of the analysis in this review, trials would have been included if they hadmet criteria A or B of theCochrane Collaboration
Handbook. Additionally, a cut-off of two points on the Jadad scale would have been used to check the assessment made by the Cochrane
Collaboration Handbook criteria if any studies had met the inclusion criteria.
Appendix 3. Methods section of 2004 version of this review
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. Where a trial was described as ’double-blind’ but it was implied that the study was randomised
and the demographic details of each group were similar, it was included. Quasi-randomised studies, such as those allocated by using
alternate days of the week, were excluded.
Types of participants
People with schizophrenia or schizoaffective disorder or any other serious mental illness, diagnosed by any criteria, irrespective of gender,
age or nationality who fulfilled the following criteria.
1. Required the use of neuroleptic drugs for more than three months.
2. Developed tardive dyskinesia (diagnosed by any criteria) during neuroleptic treatment.
3. For whom the dose of neuroleptic medication had been stable for one month or more.
Types of interventions
1. Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil): any dose.
2. Placebo or no intervention.
Types of outcome measures
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Clinical efficacy was defined as an improvement in the symptoms of tardive dyskinesia of more than 50%, on any scale, after at least
six weeks of intervention.
Outcomes of interest were classified in three categories.
1. Tardive dyskinesia changes
1.1 Any improvement in the symptoms of participants of more than 50% on any tardive dyskinesia scale*.
1.2 Any improvement in the symptoms of participants on any tardive dyskinesia scale, as opposed to no improvement.
1.3 Deterioration in the symptoms of participants, defined as any deleterious change on any tardive dyskinesia scale.
1.4 Mean change in severity of tardive dyskinesia during the trial period.
1.5 Mean difference in severity of tardive dyskinesia at the end of the trial.
2. General mental state changes
2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any
scale.
2.2 Mean difference in severity of psychiatric symptoms at the end of the trial.
3. Acceptability of the treatment
3.1 Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial.
4. Adverse effects
4.1 No clinically significant extrapyramidal adverse effects*.
4.2 Use of any antiparkinsonism drugs.
4.3 Mean score/change in extrapyramidal adverse effects.
4.4 Acute dystonia.
5. Other adverse effects, general and specific
6. Hospital and service utilisation outcomes
6.1 Hospital admission.
6.2 Mean change in days in hospital.
6.3 Improvement in hospital status (e.g. change from formal to informal admission status, use of seclusion, level of observation).
7. Economic outcomes
7.1 Mean change in total cost of medical and mental health care.
7.2 Total indirect and direct costs.
8. Quality of life/satisfaction with care for either recipients of care or carers.
8.1 No significant change in quality of life/satisfaction.
8.2 Mean score/change in quality of life/satisfaction.
9. Behaviour
9.1 Clinically significant agitation.
9.2 Use of adjunctive medication for sedation.
9.3 Aggression to self or others.
10. Cognitive response
10.1 No clinically important change.
10.2 No change, general and specific.
* Primary outcome
All outcomes were grouped into time periods - short term (less than six weeks), medium term (between six weeks and six months) and
long term (over six months).
Search methods for identification of studies
1. Electronic searching for update
1.1 Cochrane Schizophrenia Group’s trials register (September 2003) was searched using the phrase:
[((calcium* or diltiazem* or nifedipine* or nimodipine* or verapamil*) in title or (*calcium* or *diltiazem* or *nifedipine* or *ni-
modipine* or *verapamil) in title, abstract or Index terms of REFERENCE) or (calcium* or diltiazem* or nifedipine* or nimodipine*
or verapamil*) in intervention of STUDY]
The Schizophrenia Group’s trials register is based on regular searches of BIOSIS Inside, CENTRAL, CINAHL, Embase, MEDLINE
and PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources.
A full description is given in the Group’s module.
2. Details of previous electronic search
2.1. Electronic searching
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Relevant randomised trials were identified by searching several electronic databases (Biological Abstracts, Cochrane Library, Cochrane
Schizophrenia Group’s Register of trials, Embase, LILACS, MEDLINE, PsycLIT and SCISEARCH).
2.2. Cochrane Schizophrenia Group’s Register was searched using the phrase:
[calcium* or diltiazem or nifedipine or nimodipine or verapamil or (#42 = 304 or 33)]
#42 is the ’intervention’ field within the Cochrane Schizophrenia Group’s Register and 304 and 33 are codes for the calcium channel
blocking drugs within that field.
2.3. Biological Abstracts (January 1982 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for
randomised controlled trials (see Group search strategy) combined with the phrase:
[and ((tardive near (dyskine* or diskine*) or (abnormal near movement* near disorder*) or (involuntar* near movement*))]
This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with
the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil]
2.4. Embase (January 1980 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase:
[and ((tardive dyskinesia in thesaurus -subheadings, prevention, drug therapy, side effect and therapy) or (neuroleptic dyskinesia in
thesaurus -all subheadings) or (tardive or dyskines*) or (movement* or disorder*) or (abnormal or movement* or disorder*))]
This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with
the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil]
2.5. LILACS (January 1982 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase:
[and ((tardive or (dyskinesia* or diskinesia*)) or (drug induced movement disorders in thesaurus))]
This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with
the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil]
2.6. MEDLINE (January 1966 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase:
[and ((movement-disorders in MeSH / explode all subheadings) or (anti-dyskinesia-agents in MeSH / explode all subheadings) or
(dyskinesia-drug-induced in MeSH / explode all subheadings) and (psychosis in MeSH / explode all subheadings) or (schizophrenic
disorders in MeSH / explode all subheadings) or (tardive near (dyskine* or diskine*)) or (abnormal* near movement* near disorder*)
or (involuntar* near movement*))]
This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with
the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil]
2.7. PsycLIT (January 1974 to November 2000) was searched using the Cochrane Schizophrenia Group’s phrase for randomised
controlled trials (see Group search strategy) combined with the phrase:
[and ((explode movement-disorders in DE) or (explode tardive-dyskinesia in DE) or (tardive near (dyskine* or diskine*) or (abnormal*
near movement* near disorder*) or (involuntar* near movement*))]
This downloaded set of reports was hand searched for possible trials and researched, within the bibliographic package ProCite, with
the phrase [calcium* or diltiazem or nifedipine or nimodipine or verapamil]
2.8. SCISEARCH - Science Citation Index
Each of the included studies was sought as a citation on the SCISEARCH database. Reports of articles that have cited these studies
were inspected in order to identify further trials.
3. Reference searching
The references of all identified studies were also inspected for more studies.
4. Personal contact
The first author of each included study was contacted for information regarding unpublished trials.
Data collection and analysis [For definitions of terms used in this, and other sections, please refer to the Glossary.]
1. Selection of studies
KS-W and John McGrath, working independently, inspected each reference identified by the search to see if the study was likely
to be relevant. The full article was obtained for articles that could possibly have been relevant or to provide clarification in cases of
disagreement between the two reviewers. These articles were then inspected, again independently, to assess their relevance to this review.
Where resolving disagreement by discussion was not possible, the article was added to those awaiting assessment and the authors of the
study were contacted for clarification. For the 2003 update, JR independently inspected citations from the update search (2003) and
identified relevant abstracts. Full reports of the abstracts meeting the review criteria were obtained and inspected by JR.
2. Assessment of methodological quality
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The methodological quality of the trials included in this review would have been assessed using the criteria described in the Cochrane
Handbook (Clarke 2003) and the Jadad Scale (Jadad 1996). The former is based on the evidence of a strong relationship between the
potential for bias in the results and the allocation concealment (Schulz 1995) and is defined as below:
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (unclear allocation concealment)
C. High risk of bias (inadequate allocation concealment)
The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale is made up of three items:
1. Was the study described as randomised?
2. Was the study described as double-blind?
3. Was there a description of withdrawals and dropouts?
Each item receives one point if the answer is positive. In addition, a point can be deducted or added according to the description of
either the randomisation or the blinding/masking procedures.
For the purpose of the analysis in this review, trials would have been included if they had met criteria A or B of the Handbook.
Additionally, a cut-off of two points on the Jadad scale would have been used to check the assessment made by the Handbook criteria
if any studies had met the inclusion criteria.
3. Data management
3.1. Data extraction
KS and JR would have independently extracted the data of the trials included; where further clarification was needed, the authors of
trials would have been contacted to provide missing data.
3.2. Assumption for those lost to follow up
Data would have been excluded from studies where more than 50% of participants in any group were lost to follow up. Regarding the
outcomes of ’aggression’, ’self harm’ and ’harm to others’, as they are major risks of non-treated acute psychotic illness, we would have
considered 5% of the people leaving the study early to have had a negative outcome. For other events, in studies with less than 50%
dropout rate, people leaving early would have been considered to have had the negative outcome, except for the event of death.
If fewer than 95% of people had been reported at two hour follow up, a sensitivity analysis would have been undertaken for primary
outcomes, to see if inclusion of these studies made a substantive change in estimate of effects. If they did, then data would have been
presented separately. The impact of including studies with high attrition rates after the two-hour period of follow up (25-50%) would
also have been analysed in a sensitivity analysis. If inclusion of data from this latter group had resulted in a substantive change in
estimate of effects of the primary outcomes, their data would not have been added to trials with less attrition, but presented separately.
3.3. Cross-over studies
This area of research commonly uses cross over studies where one person is randomly allocated the treatment only to be crossed over to
receive the comparison after a certain designated time period. Often a period of drug free ’washout’ is used between the interventions
to try and ensure that no carry-over effects of the first intervention remain before commencing the second treatment. Since the initial
publication of this review, the statistical methods for including cross-over studies in meta-analyses have developed considerably (Curtin
2002a, Curtin 2002b, Curtin 2002c, Elbourne 2002). For the condition of tardive dyskinesia, however, the reviewers remain against
use of these data within the review (see Discussion 2. Cross-over studies).
4. Data analysis
4.1. Dichotomous - yes/no - data
For binary outcomes a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI) would have been calculated.
The number needed to treat or harm statistic (NNT, NNH), and its 95% confidence interval (CI), would also have been calculated.
If heterogeneity had been found (see section 5) a random-effects model would have been used.
4.2. Continuous data
4.2.1. Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying
parametric tests to non-parametric data, the following standards would have been applied to all data before inclusion: (a) standard
deviations and means are reported in the paper or are obtainable from the authors; (b) when a scale starts from the finite number zero,
the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure
of the centre of the distribution, (Altman 1996); (c) if a scale starts from a positive value (such as PANSS which can have values from
30 to 210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skew
is present if 2SD>(S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite
start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility
of negative values (such as change on a scale), there is no way of telling whether data are non-normally distributed (skewed) or not.
It is thus preferable to use scale end point data, which typically cannot have negative values. If end point data was not available, the
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reviewers would have used change data, but these would not have been subject to a meta-analysis, and would have been reported in the
’Additional data’ tables.
4.2.2. Summary statistic: for continuous outcomes a weighted mean difference (WMD) between groups would have been estimated.
If heterogeneity had been found (see section 5) a random-effects model would have been used.
4.2.3. Valid scales: continuous data from rating scales would have been included only if the measuring instrument had been described
in a peer-reviewed journal (Marshall 2000) and the instrument was either a self report or completed by an independent rater or relative
(not the therapist).
4.2.4. Endpoint versus change data
Where possible, endpoint data would have been presented and if both endpoint and change data had been available for the same
outcomes, only the former would have been reported in this review.
4.2.5. Cluster trials: studies increasingly employ ’cluster randomisation’ (such as randomisation by clinician or practice) but analysis
and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading
to a ’unit of analysis’ error (Divine 1992) - whereby p values are spuriously low, confidence intervals unduly narrow and statistical
significance overestimated - causing type I errors (Bland 1997, Gulliford 1999). Secondly, RevMan does not currently support meta-
analytic pooling of clustered dichotomous data, even when these are correctly analysed by the authors of primary studies, since the
’design effect’ (a statistical correction for clustering) cannot be incorporated.
If clustering had not been accounted for in primary studies, we would have presented the data in a table, with a (*) symbol - to indicate
the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies
to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). If
clustering had been incorporated into the analysis of primary studies, we would also have presented these data as if from a non-cluster
randomised study, but adjusted for the clustering effect. We have sought statistical advice from theMRC Biostatistics Unit, Cambridge,
UK. Dr Julian Higgins has advised that the binary data as presented in a report should be divided by a ’design effect’. This is calculated
using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC].
If the ICC was not be reported we would have assumed it to be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented
in the report, synthesis with other studies would have been possible using the generic inverse variance technique.
5. Test for inconsistency
Firstly, consideration of all the included studies within any comparison would have been undertaken to estimate clinical heterogeneity.
Then visual inspection of graphs would have been used to investigate the possibility of statistical heterogeneity. This would have been
supplemented employing, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be
due to chance. Where the I-squared estimate included 75%, this would have been interpreted as evidence of high levels of heterogeneity
(Higgins 2003). Data would then have been re-analysed using a random-effects model to see if this made a substantial difference. If it
did, and results became more consistent, falling below 75% in the estimate, the studies would have been added to the main body trials.
If using the random-effects model did not make a difference and inconsistency remained high, data would not have been summated,
but presented separately and reasons for heterogeneity investigated.
6. Addressing publication bias
Data from all identified and selected trials would have been entered into a funnel graph (trial effect versus trial size) in an attempt to
investigate the likelihood of overt publication bias.
7. Sensitivity analyses
We intended to undertake an analysis of the primary outcomes comparing the results when completer-only data were used with analyses
on an intention-to-treat basis.
WH A T ’ S N E W
Last assessed as up-to-date: 26 April 2017.
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Date Event Description
18 October 2017 New citation required but conclusions have not
changed
New data added does not change previous conclusions.
26 April 2017 New search has been performed Update search run 26 April, 2017. Eight records found
and assessed by editorial base at Cochrane Schizophre-
nia, none of the records found were relevant to this re-
view. The records were all added to Studies awaiting
classification of Miscellaneous treatments for antipsy-
chotic-induced tardive dyskinesia (see also Results of
the search)
16 May 2016 Amended Title changed from ’Calcium channel blockers for neu-
roleptic-induced tardive dyskinesia’. Three new in-
cluded trials added (Loonen 1992; Schwartz 1997;
Zeng 1994), analyses and text updated, outcomes list
updated due to patient consultation, Summary of
findings table updated, conclusions not substantially
changed
16 July 2015 Amended Update search run July 2015.
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 3, 1997
Date Event Description
17 October 2013 New search has been performed Update search run August 2013.
1 May 2013 Amended Contact details updated.
17 October 2012 Amended Contact details updated.
31 August 2011 New citation required but conclusions have not
changed
Substantial update but no change to conclusions
14 April 2010 New search has been performed New search undertaken, no new studies, substantially
reformatted and findings clarified
11 November 2009 Amended Contact details updated.
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(Continued)
25 April 2008 Amended Converted to new review format.
22 October 2003 New citation required and conclusions have changed Substantive amendment
3 October 2003 Amended Minor revision
3 September 2003 New search has been performed New studies found and included or excluded
21 November 2000 Amended Conclusions changed
30 July 1999 Amended Reformatted
27 August 1997 New search has been performed New search.
2 September 1996 Amended Review first published
C O N T R I B U T I O N S O F A U T H O R S
AE (2011 and 2013 update): selected trials updated the methods, searched literature, helped rewrite the report.
KSW: protocol development, searching, data extraction, data assimilation, report writing.
HB (2015 update): trial selection, data extraction and assimilation, ’Summary of findings’ table, report writing.
CEA (2011 and 2015 updates): report writing.
D E C L A R A T I O N S O F I N T E R E S T
AE: none known.
KSW is the Deputy Editor-in-Chief for Cochrane and Cochrane Innovations. When the NHIR HTA programme grant was awarded
that included to update this review, Karla was the Managing Director of Enhance Reviews Ltd.
HBworked for Enhance Reviews Ltd during preparation of this review andwas paid for her contribution to this review. Enhance Reviews
Ltd is a private company that performs systematic reviews of literature. HB works for Cochrane Response, an evidence consultancy
linked to Cochrane that take commissions from healthcare guideline developers and policy makers.
CEA: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Association for evidence-based medicine, Damascus, Syrian Arab Republic.
www.a4ebm.org
• Kalamoun University, Deir Atia, Syrian Arab Republic.
• Enhance Reviews Ltd, Wantage, UK.
• University of Nottingham, Nottingham, UK.
• Modern Psychiatry Hospital, Syrian Arab Republic.
External sources
• NIHR HTA Project Grant, reference number: 14/27/02, UK.
Salary support for Hanna Bergman.
Support for patient involvement consultation.
Support for traceable data database.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have substantively reworded the protocol of this review. We consider that this rewording represents an improvement in clarity but,
also, that it did not substantively change our procedures by which we undertook the review. For the record, the methods section of the
previous version of this review is reproduced in Appendix 3.
For the 2015 update, the biggest changes to affect the review methods were to:
1. change the title from ’Calcium channel blockers for neuroleptic-induced tardive dyskinesia’ to ’Calcium channel blockers for
antipsychotic-induced tardive dyskinesia;’ and
2. update list of outcomes following consultation with consumers.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [∗adverse effects]; Calcium Channel Blockers [∗therapeutic use]; Dyskinesia, Drug-Induced [∗drug therapy];
Schizophrenia [drug therapy]
MeSH check words
Humans
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